5 Best Penny Stocks to Buy Before They Explode

2. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

On May 7, 2026, Pacific Biosciences of California, Inc. (NASDAQ:PACB) reported Q1 EPS of (12c), versus the consensus estimate of (13c). Revenue totaled $37.18M, versus the consensus estimate of $39.98M. President and CEO Christian Henry said the company continued to see increasing clinical adoption of HiFi, contributing to another record quarter for consumables revenue, though instrument revenue, particularly from Vega, came in below expectations. Henry added that PacBio made progress on several initiatives, including the expansion of the SPRQ-Nx beta program following positive early feedback on the new chemistry. Based on those results, the company plans a broader commercial rollout to all Revio customers later this month, which management believes could further support consumables growth and Revio demand. Henry also noted that PacBio was selected by Basecamp Research to support the Trillion Gene Atlas project, which could become the world’s largest and most diverse high-fidelity metagenomic dataset. PacBio sees FY26 revenue of $165M-$175M, versus the consensus estimate of $174.42M.

Last month, Pacific Biosciences of California, Inc. (NASDAQ:PACB) and Lucid Genomics announced that Lucid Genomics joined the PacBio Compatible partner program as a tertiary analysis solution for data generated using PacBio long-read sequencing platforms. Lucid Genomics Founder and CEO Dr. Uira Souto Melo said the designation marks an important milestone for both the company and its users, adding that long-read sequencing continues to unlock genomic regions and patterns that were previously difficult to analyze.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) designs, develops, and manufactures sequencing technologies used to address genetically complex challenges.